Narayan Neupane, MD
Pulmonary Disease · Gastonia, NCNPI 1255578878
Payments from drug & device makers
Across 179 payments — averaging $56.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Medtronic$2K
- Inspire Medical Systems, Inc.$1K
- Olympus Corporation Of The Americas$976
- Pulmonx Corporation$822
- GSK$372
- plus $3K from 34 others
What the payments were for
- Travel & lodging$3,62136%
- Food & beverage$4,05440%
- Education$2,50025%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 4 | $2,705 |
| Medtronic | 13 | $1,530 |
| Inspire Medical Systems, Inc. | 16 | $1,260 |
| Olympus Corporation Of The Americas | 6 | $976 |
| Pulmonx Corporation | 8 | $822 |
| GSK | 24 | $372 |
| AstraZeneca | 18 | $340 |
| Boehringer Ingelheim | 13 | $256 |
| Actelion Pharmaceuticals US, Inc. | 7 | $195 |
| United Therapeutics Corporation | 3 | $178 |
| Sanofi | 5 | $151 |
| Insmed, Inc. | 6 | $144 |
| Verona Pharma, Inc. | 2 | $127 |
| Grifols USA, LLC | 5 | $109 |
| Merck | 5 | $107 |
| Amgen | 5 | $101 |
| Pfizer | 4 | $81 |
| Philips North America LLC | 3 | $76 |
| 3b Medical, Inc. | 2 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Baxter Healthcare | 2 | $48 |
| Jazz Pharmaceuticals Inc. | 2 | $47 |
| Insulet Corporation | 2 | $45 |
| Mylan Specialty L.p. | 2 | $44 |
| Mallinckrodt Enterprises LLC | 2 | $42 |
| Harmony Biosciences LLC | 2 | $40 |
| Tactile Systems Technology Inc | 2 | $38 |
| CSL Behring | 1 | $34 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $22 |
| Novartis | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Circassia Inc. | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Electromed, Inc. | 1 | $15 |
| Advanced Respiratory, Inc | 2 | $14 |
| Genentech USA, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,175 in reported general payments places this provider in the 70th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 610 | $434,084 |
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 11 | $287,865 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 136 | $103,265 |
| Breo ElliptaFluticasone/Vilanterol | 102 | $41,556 |
| Pirfenidone | 22 | $40,233 |
| Spiriva RespimatTiotropium Bromide | 49 | $30,053 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 46 | $29,957 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 29 | $15,420 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $9,219 |
| Arnuity ElliptaFluticasone Furoate | 34 | $7,787 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 324 | $6,410 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 26 | $6,336 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $3,968 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $3,386 |
| Ventolin HfaAlbuterol Sulfate | 50 | $3,283 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $372 | $498,847775 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $340 | $112,484173 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $256 | $60,01095 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Gastonia
- Anup BanerjeeGastonia$2.1M
- Mikell JarrattGastonia$1.7M
- Emeka EziriGastonia$252K
- Raed SuleimanGastonia$195K
- Selwyn SpangenthalCharlotte$7M
- Thomas SternHuntersville$5.2M
- Laurie SnyderDurham$3.8M
- Scott PalmerDurham$3.8M
- Michael PritchettPinehurst$2.2M
- Hubert FordChapel Hill$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.